Profile data is unavailable for this security.
About the company
Checkmate Pharmaceuticals, Inc. is a clinical-stage biotechnology company. The Company is focused on developing and commercializing its technology to harness the power of the immune system to combat cancer. Its product candidate, CMP-001, is a differentiated Toll-like receptor 9 (TLR9), agonist delivered as a biologic virus-like particle (VLP), utilizing a CpG-A oligonucleotide as a key component. When injected into a tumor, CMP-001 is designed to trigger the body’s innate immune system, thereby altering the tumor microenvironment and directing activated anti-tumor T cells to attack both the injected tumor and also tumors throughout the body. The Company is also developing CMP-001 in combination with several checkpoint inhibitor immunotherapies in melanoma and head and neck cancer.
- Revenue in USD (TTM)0.00
- Net income in USD-47.44m
- Incorporated2015
- Employees25.00
- LocationCheckmate Pharmaceuticals Inc245 Main Street, 2Nd FloorCAMBRIDGE 02142United StatesUSA
- Phone+1 (978) 503-2124
- Fax+1 (302) 655-5049
- Websitehttp://checkmatepharma.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Aptevo Therapeutics Inc | 6.73m | -28.59m | 131.13m | 58.00 | -- | 12.48 | -- | 19.48 | -7.85 | -7.67 | 1.83 | 2.36 | 0.1432 | -- | -- | 116,034.50 | -60.84 | -66.64 | -99.17 | -90.59 | -- | -- | -424.84 | -538.61 | -- | -- | 0.5846 | -- | -- | -33.69 | 28.19 | -- | -43.49 | -- |
| Yumanity Therapeutics Inc | 10.43m | -49.59m | 134.67m | 46.00 | -- | 2.75 | -- | 12.91 | -18.64 | -18.64 | 2.35 | 4.80 | 0.1261 | -- | -- | 237,000.00 | -68.08 | -60.13 | -81.16 | -68.85 | -- | -- | -539.81 | -966.61 | -- | -20.70 | 0.2374 | -- | 37.92 | 9.85 | 14.10 | -- | -1.33 | -- |
| Checkmate Pharmaceuticals Inc | 0.00 | -47.44m | 135.59m | 25.00 | -- | 1.21 | -- | -- | -2.20 | -2.20 | 0.00 | 5.20 | 0.00 | -- | -- | 0.00 | -69.32 | -- | -76.89 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -22.43 | -- | -- | -- |
| Catalyst Biosciences Inc | 6.05m | -74.63m | 135.74m | 36.00 | -- | 1.30 | -- | 22.44 | -3.34 | -3.34 | 0.2675 | 3.32 | 0.0527 | -- | 5.10 | 168,027.80 | -64.99 | -46.96 | -73.30 | -61.83 | -1.90 | -- | -1,233.69 | -804.52 | -- | -- | 0.00 | -- | -- | 64.29 | -1.93 | -- | -0.3704 | -- |
| Concert Pharmaceuticals Inc | 7.90m | -76.96m | 136.10m | 71.00 | -- | 1.19 | -- | 17.23 | -2.37 | -2.37 | 0.2439 | 3.54 | 0.0483 | -- | 197.50 | 111,267.60 | -47.03 | -20.63 | -50.52 | -21.91 | -- | -- | -974.15 | -100.30 | -- | -- | 0.00 | -- | 633.70 | -34.73 | 4.35 | -- | -24.71 | -- |
| OncoSec Medical Inc | 0.00 | -42.34m | 136.36m | 42.00 | -- | 2.85 | -- | -- | -1.51 | -1.51 | 0.00 | 1.22 | 0.00 | -- | -- | 0.00 | -82.40 | -113.86 | -98.07 | -137.28 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -39.56 | -- | -- | -- |
| LogicBio Therapeutics Inc | 2.89m | -33.45m | 136.68m | 39.00 | -- | 2.51 | -- | 47.23 | -1.24 | -1.24 | 0.105 | 1.69 | 0.0472 | -- | -- | 74,205.13 | -54.53 | -- | -60.93 | -- | -- | -- | -1,155.77 | -- | -- | -29.88 | 0.1567 | -- | -- | -- | 18.71 | -- | -- | -- |
| Imara Inc | 0.00 | -44.40m | 137.24m | 27.00 | -- | 1.81 | -- | -- | -2.55 | -2.55 | 0.00 | 4.29 | 0.00 | -- | -- | 0.00 | -46.25 | -- | -48.91 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -109.77 | -- | -- | -- |
| Otonomy Inc | 203.00k | -45.18m | 137.58m | 56.00 | -- | 2.10 | -- | 677.74 | -1.03 | -1.03 | 0.0044 | 1.16 | 0.0025 | -- | -- | 3,625.00 | -55.28 | -50.47 | -63.93 | -54.91 | -345.32 | -111.93 | -22,255.17 | -9,626.44 | 7.14 | -30.83 | 0.2134 | -- | -54.50 | -- | -0.1254 | -- | -41.87 | -- |
| Liquidia Corp | 3.82m | -54.15m | 137.73m | 51.00 | -- | 1.83 | -- | 36.02 | -1.49 | -1.49 | 0.1016 | 1.45 | 0.0541 | -- | -- | 74,965.88 | -76.69 | -- | -92.36 | -- | 75.64 | -- | -1,416.45 | -- | -- | -62.42 | 0.1499 | -- | -90.84 | -- | -25.60 | -- | -- | -- |
| Rayont Inc | 1.60m | 330.00k | 137.89m | -- | 275.36 | 35.59 | 287.24 | 86.39 | 0.0106 | 0.0106 | 0.0537 | 0.0816 | 0.5022 | -- | 3.64 | -- | 10.38 | -66.79 | 13.85 | -172.86 | 61.32 | 13.62 | 20.67 | -146.81 | 0.627 | -14.90 | 0.1829 | -- | -- | -23.91 | 90.03 | -- | -- | -- |
| Eyenovia Inc | 4.00m | -19.67m | 138.07m | 31.00 | -- | 11.27 | -- | 34.52 | -0.8634 | -0.8634 | 0.1736 | 0.4738 | 0.1828 | -- | 6.32 | 129,032.30 | -89.90 | -107.55 | -158.27 | -145.77 | 60.00 | -- | -491.77 | -3,342.16 | -- | -1,362.87 | 0.0825 | -- | -- | -- | 6.56 | -- | 120.87 | -- |
| Odonate Therapeutics Inc | 0.00 | -129.96m | 139.40m | 137.00 | -- | 1.32 | -- | -- | -3.79 | -3.79 | 0.00 | 2.73 | 0.00 | -- | -- | 0.00 | -85.25 | -58.36 | -105.34 | -65.14 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -12.99 | -- | -- | -- |
| Biomx Inc | 0.00 | -32.59m | 139.88m | 95.00 | -- | 2.58 | -- | -- | -1.40 | -1.40 | 0.00 | 2.23 | 0.00 | -- | -- | 0.00 | -43.01 | -- | -46.67 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -46.31 | -- | -- | -- |
Data as of Jun 17 2021. Currency figures normalised to Checkmate Pharmaceuticals Inc's reporting currency: US Dollar USD
17.50%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Clough Capital Partners LPas of 07 May 2021 | 1.55m | 7.18% |
| Sectoral Asset Management, Inc.as of 31 Mar 2021 | 541.77k | 2.51% |
| DNCA Finance SAas of 31 Dec 2020 | 505.29k | 2.34% |
| The Vanguard Group, Inc.as of 31 Mar 2021 | 360.71k | 1.67% |
| BlackRock Fund Advisorsas of 31 Mar 2021 | 303.44k | 1.40% |
| DWS Investment GmbHas of 31 Mar 2021 | 132.32k | 0.61% |
| Ensign Peak Advisors, Inc.as of 31 Mar 2021 | 119.92k | 0.55% |
| Geode Capital Management LLCas of 31 Mar 2021 | 103.43k | 0.48% |
| SSgA Funds Management, Inc.as of 31 Mar 2021 | 83.26k | 0.39% |
| Northern Trust Investments, Inc.(Investment Management)as of 31 Mar 2021 | 81.36k | 0.38% |
More ▼
Data from 26 Feb 2021 - 31 Mar 2021Source: FactSet Research Systems Inc.
